ライフサイエンスコーパス: desmoid tumor

1 with short-gut syndrome caused by recurrent desmoid tumor.

2 usion, CTNNB1 mutations are highly common in desmoid tumors.

3 familial adenomatous polyposis (FAP)-related desmoid tumors.

4 and in 29% of HG-FS cases but only in 4% of desmoid tumors.

5 and trisomy 20 are nonrandom aberrations in desmoid tumors.

6 margins is the treatment of choice for most desmoid tumors.

7 ctively followed 206 patients with extremity desmoid tumors.

8 ents with recurrent, refractory, progressive desmoid tumors.

9 Purpose Desmoid tumors (aggressive fibromatosis) arise from conn

10 In desmoid tumors, aggressive attempts at achieving negativ

11 Desmoid tumors also contained a subclass of fibrocytes l

12 A cohort of 24 desmoid tumors and 25 low-grade (LG) and 14 high-grade (

13 t certain patients with FAP at high risk for desmoid tumors and could be future targets for research.

14 Medline and Embase to identify subjects with desmoid tumors and FAP.

15 Desmoid tumors and fibrosarcomas (FS) are part of a wide

16 t mortality in patients with intra-abdominal desmoid tumors and identified additional risk factors ab

17 iate between histologically similar cases of desmoid tumors and LG-FS.

18 tality rate of patients with intra-abdominal desmoid tumors and to identify prognostic factors for th

19 Desmoid tumors are a group of benign, invasive, solid tu

20 The biology and natural history of desmoid tumors are an enigma.

21 Desmoid tumors are associated with a variable and unpred

22 Desmoid tumors are locally invasive fibromatous tumors,

23 Desmoid tumors are nonmalignant neoplasms of mesenchymal

24 INTRODUCTION: Intra-abdominal desmoid tumors are one of the leading causes of death in

25 nown regarding the molecular determinates of desmoid tumor behavior.

26 k has focused on the role of beta-catenin in desmoid tumor biology.

27 not metastasize; however, locally aggressive desmoid tumors can cause severe morbidity and loss of fu

28 ly induces cell death on primary FAP-related desmoid tumor cells in culture.

29 plex multidisciplinary management needed for desmoid tumor control may underlie significantly increas

30 22 specimens from 19 patients diagnosed with desmoid tumor, desmoplastic fibroma, periosteal desmoid

31 three intermediate connective tissue tumors: desmoid tumor (DT) or aggressive fibromatosis, tenosynov

32 To test this idea, we examined 16 desmoid tumors from FAP-associated and sporadic cases, f

33 and/or radiation and diagnosis of multifocal desmoid tumors highlight the need to develop effective s

34 There is an increased risk for desmoid tumors in individuals with APC mutations between

35 The standard management of desmoid tumors is resection, but many recur locally.

36 of mesenchymal tumors, we hypothesized that desmoid tumors may arise in patients with FAP after MSCs

37 Hedgehog and Notch signaling, suggests that desmoid tumors may respond to therapies targeting these

38 the treatment of 10 children for progressive desmoid tumor not amenable to standard surgical or radia

39 moid tumor, desmoplastic fibroma, periosteal desmoid tumor, osteofibrous dysplasia, or fibrous dyspla

40 Patients and Methods Seventeen patients with desmoid tumors received PF-03084014 150 mg orally twice

41 After the transplant, the desmoid tumor recurred in the thoracic wall twice and wa

42 the 10 recipients experienced intraabdominal desmoid tumor recurrence or developed de novo visceral a

43 ly higher percentages and numbers of primary desmoid tumor referrals to UTMDACC was observed in the m

44 The term fibromatosis or desmoid tumor refers to a group of benign fibrous growth

45 Treatment of desmoid tumors remains a challenge, but new chemotherapy

46 Together, our findings argue that desmoid tumors result from the growth of MSCs in a wound

47 In contrast, desmoid tumors showed a normal phenotype with these mark

48 Given the variable clinical course of desmoid tumors, the interpretation of factors classicall

49 th the increase of tumor aggressiveness from desmoid tumors to LG-FS to HG-FS.

50 ospective review of 189 consecutive cases of desmoid tumor treated with surgical resection, resection

51 MSC cell line derived from an FAP-associated desmoid tumor, we confirmed an expected loss in the expr

52 current lack of effective treatment against desmoid tumors, we advocate that endostatin gene therapy

53 ith stage I, II, III, and IV intra-abdominal desmoid tumor were 95%, 100%, 89%, and 76% respectively

54 (two patients) or recurrent (eight patients) desmoid tumor were treated with VBL and MTX for 2 to 35

55 A total of 154 patients with intra-abdominal desmoid tumors were included in the study.

56 rse of a patient with Gardner's syndrome and desmoid tumor who had multiple enterectomies and gradual

57 fit in patients with refractory, progressive desmoid tumors who receive long-term treatment.

58 gut with duodenal adenomatosis and extensive desmoid tumors with pancreaticoduodenal involvement dict

59 otherapy with VBL and MTX appears to control desmoid tumor without significant acute or long-term mor